UB
RARE icon

UMB Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

UMB Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Sell
494
-289
-37% -$7.18K ﹤0.01% 1747
2026
Q1 		$16.4K Buy
783
+272
+53% +$6.13K ﹤0.01% 1671
2025
Q4 		$11.8K Sell
511
-12
-2% -$395 ﹤0.01% 1759
2025
Q3 		$15.7K Sell
523
-104
-17% -$3.12K ﹤0.01% 1524
2025
Q2 		$22.8K Buy
627
+100
+19% +$3.6K ﹤0.01% 1340
2025
Q1 		$19.1K Sell
527
-273
-34% -$11.4K ﹤0.01% 1340
2024
Q4 		$33.7K Sell
800
-233
-23% -$11.6K ﹤0.01% 1067
2024
Q3 		$57.4K Buy
1,033
+75
+8% +$3.82K ﹤0.01% 830
2024
Q2 		$39.4K Buy
958
+352
+58% +$15K ﹤0.01% 877
2024
Q1 		$28.3K Hold
606
– – ﹤0.01% 970
2023
Q4 		$29K Buy
606
+329
+119% +$12.8K ﹤0.01% 953
2023
Q3 		$9.88K Sell
277
-157
-36% -$6.22K ﹤0.01% 1296
2023
Q2 		$20K Buy
+434
New +$20.1K ﹤0.01% 1096

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

UMB Bank's RARE Position: Q2 2026 in Review

UMB Bank reduced its Ultragenyx Pharmaceutical (RARE) stake by 37% in Q2 2026, selling an estimated $7.18K and leaving 494 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

UMB Bank first reported a position in RARE in Q2 2023 and has held it in 13 quarters since. The position peaked at $57.4K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • UMB Bank held 494 shares of Ultragenyx Pharmaceutical worth $16.5K as of Q2 2026.
  • UMB Bank sold 289 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.18K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1747 holding.
  • UMB Bank first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • UMB Bank's Ultragenyx Pharmaceutical position peaked at $57.4K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.